Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal

MT Newswires Live06-22

Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.

Instead of issuing $2 million in Galmed stock at closing, Galmed increased the cash payment by $800,000 to $3.3 million, with the balance structured as an earnout of up to $2 million tied to net sales revenue, starting in Q3 2027, according to a US Securities and Exchange Commission filing.

Galmed said the parties have further agreed to accelerate earnout payments upon the earlier of a sale or licensing of Colospan or its assets, or Galmed raising at least $17.5 million in gross proceeds through equity financings.

Galmed said Colospan is now its wholly owned subsidiary.

Galmed shares were down 6% in Monday trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645078838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645078838","market":"hk","top_or_hot":-1,"title":"Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal","media":"MT Newswires Live","content":"<html><body><p> Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.</p><p>Instead of issuing $2 million in Galmed stock at closing, Galmed increased the cash payment by $800,000 to $3.3 million, with the balance structured as an earnout of up to $2 million tied to net sales revenue, starting in Q3 2027, according to a US Securities and Exchange Commission filing.</p><p>Galmed said the parties have further agreed to accelerate earnout payments upon the earlier of a sale or licensing of Colospan or its assets, or Galmed raising at least $17.5 million in gross proceeds through equity financings.</p><p>Galmed said Colospan is now its wholly owned subsidiary.</p><p>Galmed shares were down 6% in Monday trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.</p><p>Instead of issuing $2 million in Galmed stock at closing, Galmed increased the cash payment by $800,000 to $3.3 million, with the balance structured as an earnout of up to $2 million tied to net sales revenue, starting in Q3 2027, according to a US Securities and Exchange Commission filing.</p><p>Galmed said the parties have further agreed to accelerate earnout payments upon the earlier of a sale or licensing of Colospan or its assets, or Galmed raising at least $17.5 million in gross proceeds through equity financings.</p><p>Galmed said Colospan is now its wholly owned subsidiary.</p><p>Galmed shares were down 6% in Monday trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645078838","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645078838","pubTimestamp":1782136522,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.Instead of issuing $2 million i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLMD":"Galmed Pharmaceuticals Ltd."},"translate_title":"Galmed Pharmaceuticals根据重组交易完成对Colospan的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLMD":1.5},"content_text":"Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.Instead of issuing $2 million in Galmed stock at closing, Galmed increased the cash payment by $800,000 to $3.3 million, with the balance structured as an earnout of up to $2 million tied to net sales revenue, starting in Q3 2027, according to a US Securities and Exchange Commission filing.Galmed said the parties have further agreed to accelerate earnout payments upon the earlier of a sale or licensing of Colospan or its assets, or Galmed raising at least $17.5 million in gross proceeds through equity financings.Galmed said Colospan is now its wholly owned subsidiary.Galmed shares were down 6% in Monday trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645078838","isCrawlerRequest":true}